Browse studies

Find your next paid study

5 recruiting studies matching your filters

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus s…

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Boehringer IngelheimNCT07472517

Phase 3

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) i…

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Verified

$1,200

Gilead SciencesNCT06801834

Phase 1

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recomme…

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07564401

Phase 1

Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received pl…

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$500 – $7,500

Actual pay is set by the research site.

Yale UniversityNCT07113691

Phase 2

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tum…

Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Bindu R PotugariNCT07339059